Whilst results for cisplatin therapy mirrored those of rucaparib in vitro, in vivo cisplatin administration lead to significant differences in survival times with mice harbouring the Trp53-/-;Brca2-/- tumours exhibiting the longest survival and Trp53-/-;Nf1-/- and Trp53-/-;Pten-/- tumours having the worst survival. This evidence concerns the gene BRCA2 and neoplasm.